In a human Phase 1 trial, no dose-limiting toxicities (DLTs) were observed at lower doses. At doses above 50 mg, reversible neutropenias and thrombocytopenias were observed, and particularly evident in heavily pretreated patients. These side-effects are shared by most chemotherapies, including alkylating agents in general.
Melphalan flufenamide
Normustine
Ifosfamide
Fluorouracil
Carmustine
GemOx
Topotecan
Etoposide